| IVIG responders (N = 117) | IVIG non-responders (N = 785) | P value |
---|---|---|---|
Age, months | 31.43 ± 22.44 | 36.39 ± 27.70 | 0.07 |
Sex | |||
 Male, n (%) | 444 (56.5%) | 67 (60.3%) | 0.47 |
 Female, n (%) | 341 (43.4%) | 44 (39.6%) |  |
WBC, 103/L | 14.8 ± 4.6 | 15.2 ± 6.0 | 0.36 |
ANC, 103/L | 9.56 ± 4.4 | 11.36 ± 5.3 |  < 0.01* |
Hematocrit, % | 34.3 ± 12.7 | 35.2 ± 5.7 | 0.43 |
Platelet, 103/L | 361.46 ± 100.66 | 322.14 ± 105.44 |  < 0.01* |
AST, U/L | 79.8 ± 138.8 | 135.6 ± 201.5 |  < 0.01* |
ALT, U/L | 79.7 ± 127.9 | 159.1 ± 188.3 |  < 0.01* |
Albumin, g/dL | 3.97 ± 0.9 | 3.80 ± 0.5 | 0.06 |
Total bilirubin, mg/dL | 0.62 ± 0.8 | 1.38 ± 1.4 |  < 0.01* |
CRP, mg/dL | 8.02 ± 5.9 | 9.92 ± 6.3 |  < 0.01* |
Na, mmol/L | 136.3 ± 2.8 | 135.8 ± 2.5 | 0.09 |
NT-proBNP, pg/mL | 1231.9 ± 2136.5 | 2425.4 ± 4459.3 |  < 0.01* |
Development of CADs, n (%) | 39 (14.9%) | 117 (35.1%) |  < 0.01* |